Jiankai Technology announced that the phase III clinical trial of injectable polyethylene glycol irinotecan for the treatment of small cell lung cancer developed independently by Tianjin Jiankai Technology Co., Ltd., a wholly-owned subsidiary of the company, “JK1201I Phase III Clinical Study for the Treatment of Extensive Small Cell Lung Cancer with Recurrent or Progressive Small Cell Lung Cancer” has recently completed the enrollment of the first test subjects. Polyethylene glycol irinotecan is an innovative small-molecule long-term anti-cancer class 1 drug independently developed by the company. The drug was approved for clinical trials in January 2016.

Jiankai Technology announced that the phase III clinical trial of injectable polyethylene glycol irinotecan for the treatment of small cell lung cancer developed independently by Tianjin Jiankai Technology Co., Ltd., a wholly-owned subsidiary of the company, “JK1201I Phase III Clinical Study for the Treatment of Extensive Small Cell Lung Cancer with Recurrent or Progressive Small Cell Lung Cancer” has recently completed the enrollment of the first test subjects. Polyethylene glycol irinotecan is an innovative small-molecule long-term anti-cancer class 1 drug independently developed by the company. The drug was approved for clinical trials in January 2016.